Publications

5900 Results

3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801

Authors
V Sondak;S Patel;M Othus;V Prieto;M Lowe;E Buchbinder;Y Chae;P Wright;J Hyngstrom;C Lao;T-G Truong;S Chandra;K Kendra;C Devoe;A Mangla;A Ikeguchi;J Kirkwood;L Korde;J Moon;A Ribas
Journal / Conference
ESMO (Berlin, Germany 17-21 October 2025)
Year
2025
Research Committee(s)
Melanoma
Study Number(s)
S1801

A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Authors
YK Chae;M Othus;S Patel;R Aljumaly;K Win;T Pejovic;S Thomas;W Robinson;H Kim;I Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock
Journal / Conference
Cancer Communications Aug;45(8):976-986
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID40402690
PMC
PMC12365539
Study Number(s)
S1609

Impact of Sirtuin genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)

Authors
P Mittal;Y Yang;K Ashouri;S Soni;F Battaglin;S Algaze;P Jayachandran;L Torres-Gonzalez;W Zhang;F Ou;A Venook;J Millstein;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

The prognostic impact of SLFN11 gene expression in metastatic colorectal cancer (mCRC) (Alliance)

Authors
H Arai;Y Yang;J Millstein;K Ashouri;F Ou;F Innocenti;F Battaglin;S Algaze;S Soni;W Zhang;A Venook;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Clinical and Molecular Characterization of FAP and SPP1 in Colorectal Cancer, CALGB (Alliance)/SWOG 80405 and Real-World Data

Authors
K Ashouri;Y Yang;J Millstein;J Xiu;S Soni;S Algaze;P Mittal;L Torres-Gonzalez;U Shah;A Shields;R Goldberg;E Lou;B Weinberg;J Marshall;S Mumenthaler;A Venook;S Finley;F Battaglin;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Expression of metabolic genes affects patients (pts) outcomes in metastatic colorectal cancer (mCRC): data from CALGB/SWOG 80405 (Alliance)

Authors
F Battaglin;J Millstein;Y Yang;K Ashouri;S Soni;S Algaze;P Mittal;L Torres-Gonzalez;P Jayachandran;U Shah;W Zhang;H Hochster;F Ou;A Venook;F Innocenti;S Finley;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Evaluation of CSF1R as a Prognostic and Predictive Biomarker in Colorectal Cancer

Authors
S Algaze;Y Yang;J Millstein;F Battaglin;S Soni;S Soni;P Mittal;K Ashouri;P Jayachandran;H Arai;L Torres Gonzalez;W Zhang;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Lessons Learned from SWOG S1316: Optimizing Surgical Trial Design for Malignant Bowel Obstruction

Authors
M Farooq;N Amini;G Anderson;V Sun;G Deutsch;J Deneve;M Grant;R Krouse
Journal / Conference
Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)
Year
2025
Research Committee(s)
Palliative Care
Study Number(s)
S1316

Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT) - A randomized phase II study of Gemcitabine and NabPaclitaxel compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (NCT04233866)

Authors
E Dotan;P Catalano;L Lenchik;R Boutin;X Yao;J Ohr;K Lim;G Fisher;N Vijayvergia;S Chandana;A Kalyan;R Dunne;D Zhen;D Li;K Reiss;M Simon;J Berlin;L Waggoner;P O'Dwyer
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2186

Efficacy and Safety of Cabozantinib for Advanced Gastrointestinal Neuroendocrine Tumors (NET) after Progression on Prior Therapy: A Subgroup Analysis of the Phase III CABINET Trial (Alliance A021602)

Authors
J Strosberg;T Zemla;S Geyer;M Knopp;S Behr;S Pulsipher;J Acoba;A Shergill;E Wolin;T Halfdanarson;B Konda;N Trikalinos;B Tawfik;N Raj;S Shaheen;N Vijayvergia;A Dasari;E O'Reilly;J Meyerhardt;J Chan
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA), abstract 666
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021602